Funds & Fund Managers
|Average Manager Total Return : 33.0% (30 April 2015 - 30 April 2018)|
|1 of 12||
|2 of 12||
|3 of 12||
|4 of 12||
|5 of 12||
|6 of 12||
|7 of 12||
|7 of 12||
|7 of 12||
|10 of 12||
|11 of 12||
|12 of 12||
|Managers with less than 36 months history are below. View 1 month performance|
Neptune's Mark Martin slips on PZ Cussons slide
Shares in PZ Cussons tumble to the bottom of the FTSE 250 on profits warning, hurting fund manager backers.
Greencore serves up share slump to F&C's Wilson
Shares in food manufacturer slump on profit warning, hurting fund manager backer Thomas Wilson.
FTSE rallies as Trump faces tariffs backlash
FTSE 100 follows US markets higher as Republican House speaker Paul Ryan opposes president Donald Trump's plans to impose tariffs on metal imports.
Why White Oak Financial Planning doesn't outsource investments
The decision not to outsource investment gives Tom Wilcox-Jones, director of White Oak Financial Planning, the freedom to choose the products that best suit each individual client
Brewin hands advisers £3m model portfolio charge cut
Brewin Dolphin has cut charges on its managed portfolio service in a move which it claims will save advised clients £3 million a year.
Mothercare slump adds to UK retail woes
Profit warning from baby goods retailer adds to fears over plight of UK consumer following Debenhams slump last week.
Christmas crackers: 10 managers on the up this month
Our regular roundup of the Citywire ratings takes a look at fund managers on the rise this festive season.
Adviser Profile: Keith Churchouse of Chapters Financial
Keith Churchouse already has reason for Christmas cheer as Chapters Financial continues to grow at an impressive rate. He now wants his revamped robo-advice proposition to deliver the gift of advice to the masses
Citywire ratings: small cap stars rise up the ranks
We highlight 10 fund managers moving up the Citywire ratings, including a host of small cap big-hitters.
Indivior crashes as US court deals blow to key drug
US court ruling opens door to generic rivals of flagship drug which accounted for 80% of group's revenues last year.